Who's Got Game in Antibody Development?
Executive Summary
The handful of firms with established bioprocessing capabilities has dominating advantages in antibody drug development. Because process varies little from one antibody to another, they can wait for and quickly pounce on fast-follower opportunities, expanding production capacity in a modular fashion as demand requires--and in this way minimize target risk. Meanwhile, smaller companies, which cannot buy their way into the game nor compete in the more mature world of fast followers, are using their technology development expertise to come up with good drugs against novel targets in diseases where no antibody treatments currently exist, hoping that the novelty of the resulting products will give them the kind of leverage they haven't been able to get from platform dealmaking.
You may also be interested in...
Amgen/Abgenix: All About a Drug
Amgen is using its cash to buy near-term products-the fundamental reason behind its purchase of Abgenix. Indeed, the irony to this transaction is that while the promise of genomics generated the money Abgenix needed to stay alive, the product that ultimately made Abgenix's fortune is an antibody to an entirely pre-genomic target, the fourth in its target class to make it to market, and the second antibody to do so.
Deal Update: Taking Stock of Biogen Idec
Like the merger that created Biogen Idec, its new collaboration with PDL is an example of how biotechs can combine to help achieve critical mass. But Biogen Idec still has a lot of heavy lifting to do, especially in one key therapeutic area-oncology.
Deal Update: Taking Stock of Biogen Idec
Like the merger that created Biogen Idec, its new collaboration with PDL is an example of how biotechs can combine to help achieve critical mass. But Biogen Idec still has a lot of heavy lifting to do, especially in one key therapeutic area-oncology.